Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and
other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced,
unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic
changes of the MET gene (mutation or amplification [increase number of gene copies]). Testing
for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have
previously received treatment with chemotherapy. The number of patients to be enrolled will
depend on how many enrolled patients experience tumor size reduction. MGCD265 will be
administered orally, twice daily. The study is designed to evaluate whether the number of
patients experiencing tumor size reduction is substantially higher than would be expected
with other available treatments.